Your browser doesn't support javascript.
loading
Computational Simulation Model to Predict Behavior Changes in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Analysis of Two Regional Japanese Populations.
Suzuki, Gen; Iwakiri, Ryuichi; Udagawa, Eri; Ma, Sindy; Takayama, Ryoko; Nishiura, Hiroshi; Nakamura, Koshi; Burns, Samuel P; D'Alessandro, Paul Michael; Fernandez, Jovelle.
Afiliación
  • Suzuki G; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
  • Iwakiri R; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
  • Udagawa E; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
  • Ma S; PricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
  • Takayama R; PricewaterhouseCoopers Consulting LLC, Tokyo 100-0004, Japan.
  • Nishiura H; Health & Environment Science, Kyoto University, Kyoto 606-8601, Japan.
  • Nakamura K; Department of Public Health and Hygiene, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan.
  • Burns SP; PricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
  • D'Alessandro PM; PricewaterhouseCoopers Advisory Services LLC, Philadelphia, PA 19103, USA.
  • Fernandez J; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo 103-8668, Japan.
J Clin Med ; 12(3)2023 Jan 18.
Article en En | MEDLINE | ID: mdl-36769406
Managing inflammatory bowel disease (IBD) is a major challenge for physicians and patients during the COVID-19 pandemic. To understand the impact of the pandemic on patient behaviors and disruptions in medical care, we used a combination of population-based modeling, system dynamics simulation, and linear optimization. Synthetic IBD populations in Tokyo and Hokkaido were created by localizing an existing US-based synthetic IBD population using data from the Ministry of Health, Labor, and Welfare in Japan. A clinical pathway of IBD-specific disease progression was constructed and calibrated using longitudinal claims data from JMDC Inc for patients with IBD before and during the COVID-19 pandemic. Key points considered for disruptions in patient behavior (demand) and medical care (supply) were diagnosis of new patients, clinic visits for new patients seeking care and diagnosed patients receiving continuous care, number of procedures, and the interval between procedures or biologic prescriptions. COVID-19 had a large initial impact and subsequent smaller impacts on demand and supply despite higher infection rates. Our population model (Behavior Predictor) and patient treatment simulation model (Demand Simulator) represent the dynamics of clinical care demand among patients with IBD in Japan, both in recapitulating historical demand curves and simulating future demand during disruption scenarios, such as pandemic, earthquake, and economic crisis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Clin Med Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza